MedTrace Logo

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

NCT01033487 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2016-02-19

Study results available
· View outcomes & findings →

Summary

PF-03635659 is being developed for the treatment of chronic obstructive pulmonary disease. This is a study to examine the safety, pharmacokinetics and pharmacodynamics of PF-03635659 in patients with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

  • Pulmonary Disease, Chronic Obstructive
  • Lung Diseases
  • Respiratory Tract Diseases
  • Chronic Obstructive Airway Disease
  • COPD

Interventions

DRUG

placebo

oral inhaled formulation, single dose

DRUG

active comparator

oral inhaled formulation, single dose

DRUG

Low Dose PF-03635659

oral inhaled formulation, single dose, low dose

DRUG

Mid Dose PF-03635659

oral inhaled formulation, single dose, mid dose

DRUG

High Dose PF-03635659

oral inhaled formulation, single dose, high dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01033487 on ClinicalTrials.gov